Table 2.
Myopathies and elevation in creatine kinase levels in patients treated with immune checkpoint inhibitors, based on statin therapy, statin intensity, and the type of statin (lipophilic or hydrophilic)
| On statin (n = 861) |
No statin (n = 1897) | Low intensity (n = 111/855) |
Moderate intensity (n = 509/855) |
High intensity (n = 235/855) |
Lipophilic (n = 690/861) |
Hydrophilic (n = 171/861) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any skeletal myopathy |
20/858 | (2.3) | 13/1889 | (0.7) | 3/111 | (2.7) | 12/507 | (2.4) | 5/235 | (2.1) | 17/687 | (2.5) | 3/171 | (1.8) |
| P < 0.001 | P = 0.95 | P = 0.78 | ||||||||||||
| Inflammatory myopathy | 14/858 | (1.6) | 8/1889 | (0.4) | 2/111 | (1.8) | 8/507 | (1.6) | 4/235 | (1.7) | 13/687 | (1.9) | 1/171 | (0.6) |
| P = 0.002 | P = 0.98 | P = 0.38 | ||||||||||||
| Elevation in creatine kinase levels | 49/245 | (20.0) | 65/454 | (14.3) | 7/38 | (18.4) | 30/134 | (22.4) | 11/72 | (15.3) | 43/199 | (21.6) | 6/46 | (13.0) |
| P = 0.067 | P = 0.46 | P = 0.26 | ||||||||||||
| Grade 1 | 33/245 | (13.5) | 48/454 | (10.6) | 4/38 | (10.5) | 21/134 | (15.7) | 7/72 | (9.7) | 30/199 | (15.1) | 3/46 | (6.5) |
| Grade 2 | 12/245 | (4.9) | 10/454 | (2.2) | 3/38 | (7.9) | 6/134 | (4.5) | 3/72 | (4.2) | 9/199 | (4.5) | 3/46 | (6.5) |
| Grade 3 | 4/245 | (1.6) | 7/454 | (1.5) | 3/134 | (2.2) | 1/72 | (1.4) | 4/199 | (2.0) | ||||
| P = 0.15 | P = 0.74 | P = 0.31 |